CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the initiation of an international phase 3 clinical trial evaluating once-weekly oral MLN9708 plus dexamethasone in patients with relapsed or refractory light chain AL amyloidosis. The multi-center study with MLN9708, an investigational oral proteasome inhibitor, plans to enroll patients in Europe, North America, Latin America and the Asia-Pacific region.
